The European Commission (EC) has granted approval for Novartis’ Enzair Breezhaler, a drug therapy for uncontrolled asthma. The drug is utilized as a maintenance treatment for adults with asthma. “Novartis is working to reimagine medicine for people with uncontrolled asthma, who find it a challenge to achieve effective symptom and exacerbation control,” said Rod Wooten, head of Global Marketing, Novartis Pharmaceuticals. 

 
Read more here 
 

More on: